

Index

- Alcohol, Drug Abuse, and Mental Health Administration (ADAMHA) (U.S.), 76
 - National Institute on Drug Abuse (NIDA), 93
 - National Institute of Mental Health (NIMH), 93
 - Office of Science, 76
 - research on the menopause, 93-94
- Amenorrhea, 18
- American College of Obstetrics and Gynecology, guidance on hormone therapy, 46
- American College of Physicians, guidance on hormone therapy, 46
- Animal models for research, 88
- Arteriosclerosis Research Center, 88
- Baltimore Longitudinal Study of Aging (BLSA), 76
- Bellergal, 47
- Beta-blockers, 47
- Bilateral oophorectomy
 - and breast cancer, 40, 82
 - as cancer preventative, 20
 - and cardiovascular disease, 20, 26, 27, 40, 77
 - and estrogen use, 49
 - and hysterectomy, 20, 22
 - indications for, 21
 - and menopausal symptoms, 19
 - and mortality, 78
 - and osteoporosis, 20, 40, 85
 - research needs, 85-86
- Bioequivalence, for estrogen, 67
- Biofeedback, for menopausal symptoms, 48
- Bowman Gray School of Medicine, 88
- Breast cancer
 - estrogen, role in, 4, 41-43, 79-80, 86
 - mortality rates for, 24
 - research needs, 86
 - risks for, 79-80
 - and Tamoxifen, 42
- California, hormone prescribing practices in, 69
- Cardiovascular disease
 - and bilateral oophorectomy, 20, 26, 27
 - and cholesterol, 26, 27, 77-79
 - and estrogen, 4, 5, 24, 39, 40, 76-77
 - and hysterectomy, 20
 - and lipid profiles, 77-79
 - and menopause, 26
 - morbidity and disability from, 26
 - mortality rates for, 24, 26, 27
 - and progestin, 5
 - research, in women, 26
 - and research needs as related to the menopause, 87-89
 - risk factors for, 40, 80
 - treatment of, 26
- Catapress transdermal patch, 47
- Change of life; see Menopause
- Cholesterol, high-density lipoprotein (HDL)
 - and cardiovascular disease, 26, 27
 - effects of estrogen on, 77-81, 87-89
- Cholesterol, low-density lipoprotein (LDL)
 - and cardiovascular disease, 26, 27
 - effects of estrogen on, 77-81, 87-89
- CIBA, 54, 63, 71
- Climacteric, definition of, 3, 4
- Combined hormone therapy
 - administration of, 36-38, 70
 - alternatives to, 46-48, 106
 - and calcium intake, 39
 - compliance, 50
 - definition of, 5n.2
 - effects on weight gain, 90
 - FDA advice on, 66, 106
 - prescribing criterion for, 5
 - prescribing practices for, 48, 49, 66-70
 - prevalence of use of, 48-50
 - professional guidelines for use of, 46
 - and progestin, 5
 - refining risks and benefits of, 103-104
 - side effects of, 37
 - user of, 49
- Comparative Medicine Clinical Research Center, 88
- Curetab, 71
- Demographics
 - of menopausal women, 3
- Depression, menopausal, 22-23, 28, 35
- Diethylstilbestrol (DES), 92, 95
- Drug Efficacy Study Implementation (DESI) program, 63
- Dyspareunia, 19
- Dysuria, 19
- Education, need for concerning the menopause and hormone therapy, 106
- Endometrial cancer, 64
 - and estrogen therapy, 4, 36, 38, 40-41, 64
 - and progestin, 5, 36-37
- Epidemiology
 - and menopause research, 81-84
 - and selection bias, 82-83
- Estraderm
 - approved use for, 64, 106
 - marketing of, 71
- Estradiol
 - ovarian secretion of, 24
 - receptors for, 22
- Estratab, 71
- Estratest, 71
- Estrogen
 - and bone loss, 24
 - and breast cancer, 4
 - and cardiovascular disease, 24, 27
 - and endometrial cancer, 4
 - and hypertriglyceridemia, 27
 - and low-density lipoprotein cholesterol, 27
 - production of, 3, 18
 - protective effects of, 27
 - receptors for, 24

- tissues affected by, 17,36
- and vaginal dryness, 22
- and very low density lipoprotein, 27
- Estrogen replacement therapy (ERT); see Estrogen therapy
- Estrogen Therapy (ET)
 - alternatives to, 46-48
 - approved use for, 64
 - bioequivalence for, 67
 - and breast cancer, 4,41-43,79-80, 83, 86
 - cardioprotective effect of, 35-36,3940,65,77-81, 87-89
 - and compliance, 50
 - contraindications to use, 36, 65
 - drug labeling for, 63-65, 105-106
 - and endometrial cancer, 4, 36, 38,40-41
 - and hepatobiliary disease, 43
 - and hot flashes, 4, 35
 - and lipid profiles, 35,37,3940,77-79, 87
 - marketing of, 70-71
 - and menopausal symptoms, 4, 35
 - opposed vs. unopposed, 4
 - and overall mortality, 39,78
 - prescribing practices for, 4849,66-70
 - prescriptions of, 67-70
 - and prevention of bone loss, 38-39,79, 89-90
 - and renal function, 90
 - routes of administration for, 36
 - sales figures for, 63
 - and triglyceride levels, 35,79
 - and weight gain, 90
- Exercise and menopause, 39,48,91
- Follicle-stimulating hormone (FSH), in reproductive cycle, 17, 18
- Food and Drug Administration (U. S.)
 - Division of Epidemiology and Surveillance, 68
 - Fertility and Maternal Health Drugs Advisory Committee, 64-65,66
 - Generic Drugs Advisory Committee, 67
 - guidance regarding generic estrogens, 66
 - guidance regarding osteoporosis, 53
 - and women's health issues, 5
- Food, Drug, and Cosmetic Act, 63
- Framingham Study, 76-77
- General Accounting Office (U.S.), 75
- Generic estrogens, 66
- Ginseng, 48
- Glucose metabolism and the menopause, 86-87
 - effects of progestin on, 87
- Goldman, L., 105
- Gonadotropin-releasing hormone (GnRH), in reproductive cycle, 18
- Healthy user effect, 82
- Healthy Women Study, 77-78,83
- Herbal treatments, 47-48
- Hormone replacement therapy (HRT); see Combined hormone therapy
- Hormone therapy
 - definition of, 4n.2
 - weighing risks and benefits of, 5,49-50, 105
- Hot flashes
 - incidence of, 18
 - treatment of, 4,64-66
 - vasomotor symptoms of, 19
- Hypermenorrhea, 18
- Hypertriglyceridemia, 27
- Hypomenorrhea, 18
- Hysterectomy
 - age at, 21-22, 22
 - and bilateral oophorectomy, 20, 22
 - and bone loss, 20, 85
 - and breast cancer risk, 82
 - and cardiovascular disease, 20, 77
 - indications for, 21, 22
 - and mortality, 78
 - prevalence of, 19-20,20,21
 - and psychiatric symptoms, 23
 - research needs on, 85-86
- IMS, America, Ltd., 67
- Inderal, 47
- International Consensus Conference on progestin use, 46
- International Menopause Society, 51
- Involutional melancholia see Depression, menopausal
- Japan, the menopause in, 111-112
- Leisure World Study, 78
- Lipids
 - effects of estrogens on, 77-81, 87-89
- Lipid Research Clinic Mortality Followup Study, 39,78
- Lipid Research Clinic Prevalence Study, 78
- Los Angeles County Obstetrics and Gynecology Society, 69
- Luteinizing hormone (LH), in reproductive cycle, 18
- Massachusetts Women's Health Study, Part 2, 13,23,48, 49,79,83
- Menopause
 - age at, 3, 17
 - attitudes toward, 11, 13, 14-15, 16, 23
 - biology of, 15-17,22
 - and cholesterol levels, 26-27
 - clinics, **50-52**
 - and cultural factors, 13
 - definition of, 3,4, 15, 101
 - and educational materials, 55
 - effects of smoking on, 77
 - ethnicity and, 92
 - factors affecting onset of, 77
 - historical medical perspectives on, 11, 12-13
 - hormone levels in, 18
 - as "medical" condition, 14
 - mood and behavioral changes in, 22-23
 - myths regarding, 14
 - nutritional requirements and, 90
 - patient and professional education regarding, 52
 - and psychiatric syndromes, 22
 - relationship with diseases of aging, 101-102
 - research needs, 11, 15, 82, 84-91, 102
 - and roles of women, 11, 14-15, 16
 - and sexuality, 23
 - and smoking, 17-18
 - symptomatology of, 11, 15, 18-19
 - timing of, 17
- Menopause, surgical; see Hysterectomy; Bilateral oophorectomy
- Menorrhagia, 18

- Menstruation, study of, 81
- Metrorrhagia, 18
- National Cancer Institute, 42,94
- National Center for Nursing Research, 94
- National Center for Research Resources, 94
- National Disease and Therapeutic Index, 67
- National Heart, Lung, and Blood Institute, 42,76,77,78,80,94
- National Institute for Dental Research, 94
- National Institute on Aging, 76,79,94
- National Institute of Arthritis and Musculoskeletal and Skin Diseases, 80,94
- National Institute of Child Health and Human Development, 80,94
- National Institute of Diabetes and Digestive and Kidney Diseases, 80,94
- National Institute of Environmental Health Sciences, 81
- National Institutes of Health
- Computer Retrieval of Information on Scientific Projects (CRISP), 92
 - Office of Research on Women's Health, 75-76
 - research on menopause, 92-94
 - research on women's health, 5, 6,75
- National Osteoporosis Foundations, 42
- National Prescription Audit, 67
- National Surgical Adjuvant Breast and Bowel Project, 42
- Nurses' Health Study, 5,40,42,79-80,83
- Oligomenorrhea, 18
- Oral contraceptives
- and postmenopausal hormone use, 102
 - risks of use of, 39, 80
- Osteoporosis
- and age, as factor in etiology of, 24
 - and bilateral oophorectomy, 20
 - and bone mass, 25-26
 - definition of, 24
 - and fractures, 24-25
 - in hysterectomized women, 24
 - incidence of, 24, 25
 - major sites of, 24
 - and ovarian hormones, 4, 24, 25
 - research needs, 89-90
 - risk factors for, 26,40, 90
- Ovary, research needs on, 85-86
- Pennsylvania State University, 81
- Perimenopause
- attitudes toward, 23
 - definition of, 3,4, 101
 - symptomatology of, 17, 27
- Pharmacology, and hormone therapy, 91
- Physician's Desk Reference, 64,65,66
- Physician's Health Study, 84
- PMB-200, 64
- PMB-400, 64
- Postmenopausal Estrogen Progestin Intervention (PEPI) Trial, 69,80-81,83,84,87,92, 103
- Premarin
- approved use of, 63-65
 - bioequivalence for, 67
 - cost of, 106
 - marketing of, 54,70
 - prescriptions of, 68
 - sales of, 63, 106
 - use in research participants, 77, 80, 87
- Premature ovarian failure, definition of, 17
- Premenstrual syndrome (PMS), as psychiatric syndrome, 22
- Progesterone
- and bone mass, 25
 - receptors for, 22
 - in reproductive cycle, 18
- Progestins
- alternatives to, 46-47
 - approved use of, 65-66
 - and breast cancer, 43
 - and cardiovascular disease, 5, 37, 77, 87
 - and combined hormone therapy, 5, 36-38
 - and compliance, 50
 - contraindications of, 66, 70
 - and endometrial cancer, 5, 36
 - and glucose metabolism, 87
 - and hot flashes, 37,46
 - labeled indications for, 65-66
 - marketing of, 70
 - prescribing practices for, 68-70
 - side effects of, 37
- Provera, 63,80,87
- Public Health Service (U.S.)
- agenda for women's health, 75
 - Healthy People 2000,94
 - investment in menopausal and related research, 92-94
 - Task Force on Women's Health Issues, 73
- Randomized trials
- of estrogen, 81-82,83
 - need for, 102-103
- Reid-Rowell, 71
- Research
- estrogen use, 77-81
 - Federal investment in, 92-94
 - gender-specific perspective in, need for, 3
 - menopause, 11, 15,81-92
 - methodologic considerations in, 81-84
 - needs, 84-91
 - women's health, 75
- Risk perception, 49-50, 104-105
- Smoking, and menopause, 17-18
- Symptoms, menopausal, and bilateral oophorectomy, 19
- Tamoxifen, 42
- Tosteson, A.N.A., 105
- Tremin Trust Research Program on Women's Health, 81
- Tubal ligation, 86
- United States Pharmacopoeia 67
- University of California, San Diego, 54
- University of Minnesota, 81
- University of Utah, 81
- Upjohn, 63
- Urinary stress incontinence, 19
- Vaginal atrophy, 18, 19
- Veralipride, 47
- Very low density lipoprotein (VLDL), and estrogen, 27
- Vitamins, 47

126. The Menopause, Hormone Therapy, and Women's Health

Waist-to-hip ratio, 76

Women's health

 congressional interest in, 5-6

 legislation, in 102nd Congress, 6

Women's Health Initiative Trial, 84

World Health Organization, 115

Wyeth-Ayerst, 53,63,65,66,71